Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy

BACKGROUND: Sorafenib-everolimus combination therapy may be more effective than sorafenib monotherapy for hepatocellular carcinoma (HCC). To better understand this effect, we comparatively profiled the metabolite composition of HepG2 cells treated with sorafenib, everolimus, and sorafenib-everolimus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Jian-feng, Lu, Juan, Wang, Xiao-zhong, Guo, Wu-hua, Zhang, Ji-xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2015
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479262/
https://www.ncbi.nlm.nih.gov/pubmed/26092946
http://dx.doi.org/10.12659/MSM.894669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479262/
https://www.ncbi.nlm.nih.gov/pubmed/26092946
http://dx.doi.org/10.12659/MSM.894669

Ejemplares similares